Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
Wilson Therapeutics AB (publ), announced today a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver, BC, 4-8 June, 2017. The presentation highlighted results from the recently completed Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein binding agent with a unique mechanism of action for the treatment of patients with Wilson Disease. The poster was presented by Danny Bega, MD, Assistant Professor of Neurology at Northwestern University. WTX101-201 was a 24-week open-label